Live Breaking News & Updates on Highly Accurate Infusion Platform Technology

Stay updated with breaking news from Highly accurate infusion platform technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

PAVmed Announces Closing of its Public Offering of Common Stock

PAVmed Announces Closing of its Public Offering of Common Stock
02/25/2021 | 01:38pm EDT
Send by mail :
Message :
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE)
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced underwritten public offering (the “Offering”) of approximately 9.8 million shares of its common stock for gross proceeds of approximately $45 million, before deducting underwriting discounts and commissions and other offering expenses payable by PAVmed.
Cantor Fitzgerald & Co. acted as sole bookrunner for the Offering. Lake Street Capital Markets LLC and Maxim Group LLC acted as financial advisors to the Company. ....

New York , United States , Shaun Oneil , Katie Gallagher , Mike Havrilla , Capital Markets , Cantor Fitzgerald Co , Gi Health Esoguard , Exchange Commission , Maxim Group , Pavmed Inc , Globe Newswire Pavmed Inc , Accurate Infusion Platform Technology , Lake Street Capital Markets , Cantor Fitzgerald , Esophageal Cell Collection Device , Esophageal Ablation Device , Minimally Invasive Interventions , Minimally Invasive Device , Carpal Tunnel Syndrome , Infusion Therapy , Implantable Intraosseus Vascular Access Device , Highly Accurate Infusion Platform Technology , Emerging Innovations , Seriesw Warrants , Seriesz Warrants ,

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed's CarpX® Device

Share:
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE)
PAVmed Inc. (NASDAQ:PAVM, PAVMZ)) (the Company or PAVmed ), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the first U.S. patient recently underwent successful carpal tunnel release using its CarpX
® minimally invasive carpal tunnel device.
CarpX relieves the symptoms of Carpal Tunnel Syndrome (CTS) in a rapid, minimally invasive, office-based procedure that speeds patients recovery. CTS is a common workplace-related condition that causes chronic pain to patients and, as the top driver of workmen s compensation claims, imposes high costs on society.
The patient presented with symptoms of carpal tunnel syndrome to Dr. Edward J. Armbruster of Mercer-Bucks Orthopaedics, P.C., in greater Philadelphia, who performed minimally invasive carpal tunnel release using the CarpX device. In marked contrast to typical recovery times of up to several months fol ....

New Zealand , United States , Edwardj Armbruster , Shaun Oneil , Katie Gallagher , Lishan Aklog , Mike Havrilla , Lucid Diagnostics Inc , Gi Health Esoguard , Drug Administration , Exchange Commission , Pavmed Inc , Globe Newswire Pavmed Inc , Accurate Infusion Platform Technology , Carpal Tunnel Syndrome , Mercer Bucks Orthopaedics , Chief Medical Officer , Chief Executive , Esophageal Cell Collection Device , Esophageal Ablation Device , Minimally Invasive Interventions , Minimally Invasive Device , Infusion Therapy , Implantable Intraosseus Vascular Access Device , Highly Accurate Infusion Platform Technology , Emerging Innovations ,

PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under .
PAVmed Inc.January 8, 2021 GMT
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of 6.0 million shares of common stock at a price of $2.24 per share which was priced at-the-market under Nasdaq rules.
The estimated net proceeds to PAVmed from the Offering are expected to be approximately $12.4 million after deducting the placement agent’s fees and other estimated offering expenses. PAVmed plans to use the net proceeds for working capital, general corporate purposes, and to repay a portion of certain of the Company’s outstanding ....

New York , United States , Shaun Oneil , Mike Havrilla , Lucid Diagnostics Inc , Company At One Grand Central Place , Exchange Commission On , Gi Health Esoguard , Exchange Commission , Maxim Group , Pavmed Inc , Globe Newswire Pavmed Inc , Accurate Infusion Platform Technology , One Grand Central Place , Esophageal Cell Collection Device , Esophageal Ablation Device , Minimally Invasive Interventions , Minimally Invasive Device , Carpal Tunnel Syndrome , Infusion Therapy , Implantable Intraosseus Vascular Access Device , Highly Accurate Infusion Platform Technology , Emerging Innovations , Seriesw Warrants , Seriesz Warrants , Annual Report ,

PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules

PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of 6.0 million shares of common stock at a price of $2.24 per share for gross proceeds of approximately $13.4 million in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules.
The estimated net proceeds to PAVmed from the Offering are expected to be approximately $12.4 million after deducting the placement agent’s fees and other estimated offering expenses. The Offering is expected to close on or about January 8, 2021 subject to the satisfaction of customary closing conditions. ....

New York , United States , Shaun Oneil , Mike Havrilla , Lucid Diagnostics Inc , Company At One Grand Central Place , Exchange Commission On , Gi Health Esoguard , Exchange Commission , Maxim Group , Pavmed Inc , Accurate Infusion Platform Technology , One Grand Central Place , Esophageal Cell Collection Device , Esophageal Ablation Device , Minimally Invasive Interventions , Minimally Invasive Device , Carpal Tunnel Syndrome , Infusion Therapy , Implantable Intraosseus Vascular Access Device , Highly Accurate Infusion Platform Technology , Emerging Innovations , Seriesw Warrants , Seriesz Warrants , Annual Report , Quarterly Report ,

PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering

PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced registered direct offering (the “Offering”) of approximately 5.1 million shares of common stock at a price of $1.60 per share.
The estimated net proceeds to PAVmed from the Offering are expected to be approximately $7.4 million after deducting the placement agents’ fees and other estimated offering expenses. PAVmed plans to use the net proceeds for working capital, general corporate purposes, and to repay a portion of certain of the Company’s outstanding convertible notes. ....

New York , United States , Shaun Oneil , Mike Havrilla , Lucid Diagnostics Inc , Company At One Grand Central Place , Capital Markets , Exchange Commission On , Gi Health Esoguard , Exchange Commission , Maxim Group , Pavmed Inc , Accurate Infusion Platform Technology , Lake Street Capital Markets , One Grand Central Place , Esophageal Cell Collection Device , Esophageal Ablation Device , Minimally Invasive Interventions , Minimally Invasive Device , Carpal Tunnel Syndrome , Infusion Therapy , Implantable Intraosseus Vascular Access Device , Highly Accurate Infusion Platform Technology , Emerging Innovations , Seriesw Warrants , Seriesz Warrants ,